Indegene Ltd (BSE: 544172, NSE: INDGN) — Business Report / Investor Feed

Business & Distribution Evaluation — Indegene Limited (BSE: 544172)

1. Business Identity

Indegene Limited is a digital-first, life sciences commercialization company providing analytics, technology, and commercial, medical, regulatory, and safety services to biopharmaceutical, emerging biotech, and medical device companies globally [1][51][53]. The company does not engage in product manufacturing [52].

The company converted from Private Limited to Public Limited in November 2022 [46]. Indegene positions itself at the intersection of healthcare domain expertise, fit-for-purpose technology, and an agile operating model [53][51].

2. Revenue Architecture

Revenue Model Type

Pure service revenue model — 100% revenue from rendering of services [4][30]. Revenue is earned through a combination of:

• Fixed price and volume-based contracts — ₹23,933 Mn (84.3% of consolidated revenue) [FY25] [30]
• Time-and-materials contracts — ₹4,460 Mn (15.7% of consolidated revenue) [FY25] [30]

Additionally, pricing models include resource utilization with fixed price / unitized billing, and outcome-based pricing for select Omnichannel Activation Solutions [45].

Contract Type Mix (₹ Mn)

Source: [30]

Segment-level contract type mix [FY25]: ECS is overwhelmingly fixed-price (₹15,643 Mn fixed vs. ₹228 Mn T&M), while Omnichannel Activation is predominantly T&M (₹2,776 Mn T&M vs. ₹701 Mn fixed) [30].

Consolidated Revenue Summary

Sources: [9][33]

EBITDA margin contracted 90 bps in FY25 even as revenue grew 9.6%, while PAT margin expanded 130 bps — the divergence suggests operating leverage is being offset by investment spend (likely GenAI/Tectonic build-out), with below-the-line efficiencies (tax, depreciation) driving bottom-line improvement.

Quarterly Revenue Trend (₹ Mn)

Sources: [33][38][61]

Revenue Mix by Segment (₹ Mn)

¹ Renamed from "Omnichannel Activation" to "Brand Activation" effective 1 April 2025 [3][48]. ² Others mainly comprises consultancy and clinical business [43].

Sources: [18][43][48]

Segment Profitability (₹ Mn)

Source: [43]

Source: [48]

Key trend: ECS is gaining share (from 55.4% [Q1 FY25] to 60.6% [Q2 FY26]) while Brand Activation is declining (12.2% → 7.9%). The enterprise segments (ECS + EMS) together contribute 88.5% of Q2 FY26 revenue [20]. Enterprise segments grew 12.2% combined to ₹23,896 Mn in FY25, constituting 84.2% of revenues [37]. Management characterizes enterprise business (86.6% of revenue) as nondiscretionary [29].

The deliberate shift from Brand Activation (project-based, brand-by-brand agency work) toward embedded enterprise segments reflects a strategic pivot toward recurring, workflow-integrated engagements — reducing revenue volatility but increasing per-client integration depth and switching cost dependency.

Revenue Mix by Geography (₹ Mn) [FY25]

US alone accounts for ₹19,736 Mn (69.5%) of consolidated revenue [FY25] [30]. 98% of revenue is export [4].

Source: [30]

Geographic Revenue Mix Trend (%)

Sources: [21][67][61]

Standalone vs. Consolidated [FY25]

Standalone revenue includes ₹9,201 Mn from related parties (FY25), i.e., 84% of standalone sales are to subsidiaries [16][19] (S). Standalone revenue is predominantly T&M (₹9,221 Mn) with North America at ₹9,202 Mn — essentially 100% US subsidiary billing [35] (S).

Pricing Mechanism

~75% of enterprise business is recurring, ~11-12% is reoccurring (same customer, different scope under same MSA), taking repeatable business into the high 80s percentage [14]. Contract renewals happen once every 3 to 5 years, during which annual rate resets occur; productivity initiatives (automation, GenAI) offset wage hike impacts [41]. Management reports no material customer pricing pressure — "their propensity to shift or do anything based on a few dollars here or there is really not high" [29].

3. Product & Service Portfolio

Core Offerings by Segment

Sources: [3][61]

Business focus: Exclusively on innovator/patented products — "once a patent expires, the generic companies come in... that's not the segment which we operate in" [56].

Proprietary Technology & Key Differentiators

Domain expertise: 24.8% [Q1 FY26] → 26.3% [Q2 FY26] of delivery employees possess healthcare-related qualifications (MD, MBBS, PhD, BDS, MPharm, BPharm) [61]. ~600 dedicated technologists for AI/ML/innovative technologies [36].

Certifications: ISO/IEC 27001:2013, ISO/IEC 27701:2019, ISO 9001 [27][8].

Industry recognition [FY26]: Everest Group Leader in Life Sciences AI & Analytics Services for Commercial [54]; ISG Leader in LS Commercial Ops; IDC Major Player in R&D PV Technology Solutions; Avasant Innovator in Veeva Digital Services [65].

Data moat: Extensive proprietary data repository — commercial content assets across regions/therapeutic areas, proprietary information taxonomies for ML, operational data — integrated with real-world, clinical, commercial, prescription, and patient data. Data on 2 million physicians' digital propensities with algorithms for "shortest path to prescription" [27][59].

Acquisitions Expanding Portfolio

Acquisition philosophy: Tuck-in acquisitions on the agency side are positioned as "acqui-hires" — building creative/content execution capabilities in multiple geographies to support the Tectonic scaling strategy [29].

Note: Contingent consideration for CultHealth and Trilogy have been partially reversed (₹103 Mn and ₹55 Mn respectively) based on management's remeasurement [31][66], suggesting these acquisitions are underperforming original projections.

Partial earnout reversals for CultHealth (₹103 Mn) and Trilogy (₹55 Mn) signal that recent acquisitions are tracking below original deal-model projections — a pattern worth monitoring as the significantly larger BioPharm acquisition (₹9,146 Mn) carries similar earnout-linked structures.

4. Value Chain Position

Position: Indegene operates as a technology-enabled outsourced services partner spanning the life sciences commercialization value chain — from clinical development through regulatory to commercial operations [53][50].

Drug Discovery → Clinical Trials → Regulatory → Medical Affairs → Commercial Launch → Lifecycle Mgmt
                  ←————————————— Indegene's coverage ————————————→

The five value chain segments of life sciences operations are: (1) Drug discovery & clinical trials, (2) Regulatory & medical affairs, (3) Sales & marketing, (4) Pharmacovigilance, and (5) Manufacturing, supply chain & distribution. Indegene covers segments 1-4 but not manufacturing/supply chain [50][52].

Direction of Integration: Forward integration — historically focused on downstream content operations/production, now moving upstream via Tectonic into creative/brand strategy work traditionally done by Agency of Record (AOR) firms. This expands addressable budget from 5-15% to 35-50% of client marketing budgets [25][24]. Management expects Tectonic revenues to merge into larger ECS engagements over time — "the lines between upstream Tectonic work and the downstream production work... will become part of single larger engagements" [58].

Value Addition: Combines domain expertise (healthcare-qualified professionals), proprietary technology (Cortex, NEXT suite), and global delivery scale to consolidate and automate life sciences operations that were previously fragmented across multiple agencies and in-house teams [53]. Key competitive differentiator vs. generic IT companies: "Generic IT companies are not even in conversations wherever we are going... contract research organizations, agencies — those are the more credible competition" [59].

Supplier Concentration:

• 547 unique suppliers screened via Third-Party Risk Management [FY25] [19]
• 56 critical vendors identified based on spend, emissions, business continuity [19]
• No purchases from trading houses; nil sales to dealers/distributors (direct B2B model) [19]

Industry TAM: Life sciences operations spend estimated at US$176 billion [2024], growing at 6.2% CAGR (2022-2024). Sales & marketing is the largest segment at ~35% of total spend [50].

5. Distribution Architecture

Channel Structure

Indegene operates a 100% direct B2B sales model — zero sales through trading houses, distributors, or intermediaries [19]. Go-to-market is driven by:

• Dedicated business development teams with strategic account remapping for breadth and depth [38][65]
• Separate teams for large deals vs. growth accounts [65]
• Runway11 — strategic initiative for relationship and solution-oriented account management [65]
• Consulting practice repositioned with broader strategic involvement in engagements [63]
• Senior leadership additions in data & analytics, content, medical affairs, and regulatory affairs [38]
• Dedicated M&A team — 10 people focused on inorganic expansion [65]
• Indegene Digital Summit (IDS) — flagship thought leadership event; October 2024 virtual edition drew participants from 100+ leading life sciences organizations, 30+ global speakers [27]

Strategic GTM focus [FY26]: (i) Deepening existing Top 20 biopharma relationships; (ii) Expanding to mid-tier pharma; (iii) New market segments; (iv) High-value Tectonic opportunities; (v) Scaling nascent verticals [22].

Network Scale & Global Delivery Footprint

Sources: [42][11][61]

Delivery centers: India (Bengaluru HQ, Hyderabad — new center FY25), US (Princeton), UK (new London center FY25), Germany (strategic center 2023), China (Shanghai, Dalian), Japan, Singapore [8][40].

Onshore/Offshore Delivery Mix

Sources: [42][11][61]

Trend: Gradual increase in onsite mix (+320 bps over 2 years), reflecting investment in local market expertise rather than cost arbitrage. Only ~8% of US employees (~45 people) are on H1-B visas; the model is "not a staffing business and labour cost arbitrage is not the core of the business model" — talent is hired locally for regulatory expertise, healthcare practices, and market knowledge [34].

The deliberate shift toward onsite delivery (13.6% → 16.8%) combined with minimal H1-B reliance (~8% of US staff) positions Indegene favorably against potential immigration policy headwinds that affect traditional IT services peers — but it also means the cost structure carries less offshore arbitrage upside than headline "India-based IT services" classification would suggest.

Management expects revenue per employee to increase further: "the rate of growth of the number of employees would typically be lesser than the rate of growth of revenue" [60].

Technology Partnerships

• Microsoft — Strategic GenAI collaboration to help life sciences companies scale GenAI adoption [40]
• CliniOps — Strategic partnership for digital clinical trial transformation [39]
• Integration with well-established third-party technology platforms [26]
• Hyperscaler partnerships gaining traction in life sciences industry [7]

Business Continuity

BCP-DR procedures with Business Impact Analyses; continuity requirements defined in Master Service Agreements with engagement-level plans regularly tested [52].

6. Customer Profile

Customer Segments [Q1 FY26]

Sources: [42][67][61]

Key observation: While biopharma dominates (92%), medical devices and emerging biotech are showing strong growth momentum in Q2 FY26 (72% and 36% YoY respectively) [61], indicating successful diversification.

Customer Concentration Trends (LTM)

Sources: [42][67][61]

Significant de-concentration trend: Top 5 concentration dropped from 49.2% to 37.4% and Top 20 from 85.5% to 75.2% over 6 quarters — a healthy diversification of the revenue base.

Million-Dollar Client Pyramid (LTM)

Sources: [42][67][61]

The drop from 3 to 2 clients in the >$25 Mn tier reflects the loss/decline of specific large customers; however, the $10-25 Mn tier has grown from 4 to 9 clients, indicating clients are scaling up.

The sustained de-concentration from 49.2% to 37.4% for top 5 clients over 6 quarters is structurally healthy, but the decline from 3 to 2 clients in the >$25 Mn tier warrants attention — revenue broadening has not yet translated into deepening at the top of the pyramid, and the $10-25 Mn tier expansion needs to convert into mega-account relationships.

Consolidated Customer Concentration (Annual)

Sources: [44][5][53]

Standalone (S): Top customer = 37.4% of standalone revenue; top 10 = 92.9% [FY25] [32] — reflecting the concentrated intercompany billing structure.

Relationship Depth

• Contract type: Master Service Agreements (MSAs) with multi-year enterprise engagements; large deals are $3 Mn+ ACV, typically multi-year tenure [7]
• Recurring revenue: ~75% recurring, ~12% reoccurring, ~87%+ repeatable in enterprise segments [14]. ECS and EMS are "fairly robust long-term engagements" with very small one-time project component; project-by-project variability sits primarily in Brand Activation [56]
• Client stickiness: Solutions embedded in client workflows, maximizing outcomes; high retention [45]
• Credit terms: 75 to 90 days [44]
• Top 20 global biopharma served: 20 out of 20 [12]
• Land-and-expand strategy: Broadening solutions across clients' commercialization processes through consulting, up-selling and cross-selling [45]
• Customer satisfaction: CSAT surveys conducted regularly; BCP requirements embedded in MSAs [52]

Deal Win Trajectory

Revenue from existing accounts contributed 92% of beyond-top-20 growth in Q1 FY26, while new accounts contributed 8% [58].

DSO Trend

Sources: [42][9][61]

Improving trend: DSO compressed from 81 to 71 days over 6 quarters, reflecting improving collections and/or favorable contract structuring.

IT Services Sector-Specific Metrics

Sources: [42][11][61]

Cash position [Q2 FY26]: ₹12,681 Mn — declined from Q1 FY26's ₹17,280 Mn, likely reflecting the BioPharm acquisition payment (USD 104 Mn / ~₹9,146 Mn) [64][61].

Revenue per employee: Management describes it as "highest in the industry" and expects it to "inch higher" as employee growth lags revenue growth [60].

Attrition improvement: Voluntary attrition improved from 19.4% [Q1 FY24] to 16.2% [Q2 FY26] — a 320 bps improvement [42][61].

Healthcare talent deepening: Healthcare-qualified delivery staff rose steadily from 20.0% to 26.3% over 6 quarters — a deliberate strategy of hiring domain experts rather than generic IT talent [42][61].

Data Gaps

1. Revenue per employee / utilization rates — Not disclosed in available filings; management only references it qualitatively as "market leading" [60].
2. Competitive distribution comparison — Insufficient peer data (Axtria, ZS Associates, IQVIA sub-segments) for a side-by-side comparison. Credible competitors identified as CSOs, agencies, and CROs rather than generic IT companies [59].
3. Segment-level margin bridges across 3+ years — Segment results are available for FY24-FY25 and quarterly, but historical FY23 segment profitability data is not provided in these filings.
4. Individual customer names — Not disclosed; referred to by ranking only.
5. Contract tenure distribution — Specific average tenure data not provided; only anecdotal references to multi-year deals with renewals every 3-5 years [41].
6. BioPharm acquisition impact — Acquired October 2025 for USD 104 Mn; Q2 FY26 revenue may include partial contribution, but no breakout is provided [64].
7. Tectonic revenue trajectory — Only ~$2 Mn in H1 FY26 disclosed [34]; no granular projections provided.